Globus Medical Inc. Class A Common Stock vs Verisign, Inc. — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Verisign, Inc. trades at $302.35 (market cap $27.28B). The key difference: Verisign, Inc. is far larger — about 2.7× Globus Medical Inc. Class A Common Stock's market cap, and Verisign, Inc. pays a 1.07% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Verisign, Inc. for 124 Days on average.
| GMED | VRSN | |
|---|---|---|
Market Cap | $10.25B | $27.28B |
Volume | 1,108,124 | 695,583 |
Sector | Health | Technology |
52-Week High | $96.82 | $310.00 |
52-Week Low | $58.33 | $211.49 |
Typical Hold Time | 0 Days | 124 Days |
Enterprise Value | $9.76B | $28.59B |
Dividend Yield | — | 1.07% |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
VeriSign (VRSN) trades at $301.41, down 0.43% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $348. The stock shows strong profitability with a net income margin near 50% and consistent revenue growth, though recent quarterly EPS results have been mixed. Key developments include an upcoming Q3 2026 earnings report and ongoing institutional accumulation, balanced by an antitrust lawsuit and insider selling activity.
The outlook for VRSN remains positive given its dominant market position and high margins, with potential upside to analyst targets. Risks include legal challenges, competitive pressures, and valuation multiples above industry averages. Earnings performance and resolution of regulatory issues will be critical near-term catalysts for the stock.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →